🎉 M&A multiples are live!
Check it out!

Revolution Medicines Valuation Multiples

Discover revenue and EBITDA valuation multiples for Revolution Medicines and similar public comparables like Vivoryon Therapeutics, Pharming, and Galapagos.

Revolution Medicines Overview

About Revolution Medicines

Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio and SOS1 and 4EBP1/mTORC1 programs.


Founded

2014

HQ

United States of America
Employees

534

Website

revmed.com

Financials

LTM Revenue $2.1M

LTM EBITDA -$762M

EV

$4.6B

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Revolution Medicines Financials

Revolution Medicines has a last 12-month revenue of $2.1M and a last 12-month EBITDA of -$762M.

In the most recent fiscal year, Revolution Medicines achieved revenue of n/a and an EBITDA of -$678M.

Revolution Medicines expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Revolution Medicines valuation multiples based on analyst estimates

Revolution Medicines P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $11.6M n/a XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$430M -$678M XXX XXX XXX
EBITDA Margin -3716% -Infinity% XXX XXX XXX
Net Profit -$249M -$436M XXX XXX XXX
Net Margin -2148% -Infinity% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Revolution Medicines Stock Performance

As of April 15, 2025, Revolution Medicines's stock price is $36.

Revolution Medicines has current market cap of $6.8B, and EV of $4.6B.

See Revolution Medicines trading valuation data

Revolution Medicines Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$4.6B $6.8B XXX XXX XXX XXX $-3.87

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Revolution Medicines Valuation Multiples

As of April 15, 2025, Revolution Medicines has market cap of $6.8B and EV of $4.6B.

Revolution Medicines's trades at 2193.2x LTM EV/Revenue multiple, and -6.1x LTM EBITDA.

Analysts estimate Revolution Medicines's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Revolution Medicines and 10K+ public comps

Revolution Medicines Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $4.6B XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA -6.8x XXX XXX XXX
P/E -11.3x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -8.1x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Revolution Medicines Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Revolution Medicines Valuation Multiples

Revolution Medicines's NTM/LTM revenue growth is 322%

Revolution Medicines's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $1.3M for the same period.

Over next 12 months, Revolution Medicines's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Revolution Medicines's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Revolution Medicines and other 10K+ public comps

Revolution Medicines Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth -100% XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth 58% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee $1.3M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue n/a XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Revolution Medicines Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Revolution Medicines M&A and Investment Activity

Revolution Medicines acquired  XXX companies to date.

Last acquisition by Revolution Medicines was  XXXXXXXX, XXXXX XXXXX XXXXXX . Revolution Medicines acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Revolution Medicines

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Revolution Medicines

When was Revolution Medicines founded? Revolution Medicines was founded in 2014.
Where is Revolution Medicines headquartered? Revolution Medicines is headquartered in United States of America.
How many employees does Revolution Medicines have? As of today, Revolution Medicines has 534 employees.
Who is the CEO of Revolution Medicines? Revolution Medicines's CEO is Dr. Mark A. Goldsmith, M.D., PhD.
Is Revolution Medicines publicy listed? Yes, Revolution Medicines is a public company listed on NAS.
What is the stock symbol of Revolution Medicines? Revolution Medicines trades under RVMD ticker.
When did Revolution Medicines go public? Revolution Medicines went public in 2020.
Who are competitors of Revolution Medicines? Similar companies to Revolution Medicines include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Revolution Medicines? Revolution Medicines's current market cap is $6.8B
What is the current revenue of Revolution Medicines? Revolution Medicines's last 12-month revenue is $2.1M.
What is the current EBITDA of Revolution Medicines? Revolution Medicines's last 12-month EBITDA is -$762M.
What is the current EV/Revenue multiple of Revolution Medicines? Current revenue multiple of Revolution Medicines is 2193.2x.
What is the current EV/EBITDA multiple of Revolution Medicines? Current EBITDA multiple of Revolution Medicines is -6.1x.
Is Revolution Medicines profitable? Yes, Revolution Medicines is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.